Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > New Research Could Provide Key… >

New Research Could Provide Key to Overcoming Resistance to HER2 Targeted Cancer Treatments

Published: June 11, 2014.
Released by Trinity College Dublin  

Dublin, Ireland, June 11th, 2014 – Scientists from the School of Pharmacy & Pharmaceutical Sciences, Trinity College Dublin have made a significant discovery of a new biomarker which may help overcome resistance to newer and more targeted anti-cancer drugs, such as Herceptin, for HER2 positive cancers. These findings may also help the early identification of patients who will benefit more from these treatments.

The researchers, led by Professor Lorraine O'Driscoll, Associate Professor of Pharmacology, Trinity, studied breast cancer cells and their extracellular vesicles (exosomes), which are 'packages' of information released out of cells. They discovered a molecule called Neuromedin U (NmU) which is strongly associated with resistance to the new anti-cancer drugs for HER2 positive cancers. This suggests NmU could be used as a biological marker to indicate the likelihood of responsiveness in a particular patient and may also be very important in the management of resistance to these drugs. The findings have just been published in leading international, peer reviewed journal: Cancer Research, the most frequently cited cancer journal in the world.

About one quarter of breast cancer patients are known as being HER2 positive, where the protein HER2 is found at greater amounts on cancer cells compared to normal cells and which is associated with a poorer prognosis for the patient. A relatively new range of targeted anti-cancer drugs became available in recent years to treat patients with HER2 positive breast cancer and some other cancers such as HER2 positive gastric cancer. The best known one is Herceptin (trastuzumab), but there are other newer drugs in this family, including lapatinib, neratinib, afatinib, pertuzumab, T-DM1.

Speaking about the challenges some patients face with these newer anti-cancer drugs, Professor O'Driscoll said: "Many patients with HER2 positive tumours gain huge benefit from these drugs. Unfortunately, however, some who seem suitable candidates based on a HER2 test, don't gain the maximum intended benefit from these treatments. They may have a natural level of resistance to the treatment which is not detectable with currently available tests, while some other patients respond at first but may then become unresponsive or develop resistance to the treatments."

Professor O'Driscoll continued: "Clinicians urgently need ways of predicting which patients with 'HER2 tumours' are likely to gain real benefit, both to ensure patients are given the optimal treatments and to ensure these very costly drugs are used where they will have the most benefit. Our discovery may offer a new way to predict or identify both innate and acquired resistance, overcome it and potentially block or prevent resistance. This would allow patients to get the full benefit from these particular anti-cancer treatments and help other patients to be more quickly identified and receive the treatment options which are more appropriate for them."

The scientists also found that the levels of NmU outside the cells reflects that within the cells indicating it may be used as an 'extracellular' blood-based marker. This could allow clinicians to access and sample the levels of NmU through a minimally-invasive blood test compared to testing biomarkers within tissues.

They also found that by tweaking NmU's amounts in the cells, they could restore sensitivity to this family of anti-cancer drugs and offer an approach which may help prevent or overcome the serious resistance problem.

The research team conducted other studies which found that blocking NmU also significantly slowed the tumour's growth in the body and they plan to conduct further studies in this area.

The intellectual property has been protected to facilitate the translation of these discoveries to the benefit of patients with two patents pending in Europe and the US. This will be aided by the team's collaboration with the All Ireland Oncology Research Group (ICORG).




The above story is based on materials provided by Trinity College Dublin.

Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


comments powered by Disqus


Related »

Cells 
5/21/14 
Cancer Avatars for Personalized Medicine
Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have used computer simulations of …
Cancer 
8/7/12 
Lower Risk of Serious Side-effects in Trials of New Targeted Drugs
Patients in early clinical trials of new-style targeted cancer therapies appear to have a much lower risk of the …
Cancer 
5/14/15 
Contraceptive And Cholesterol-lowering Drugs Used to Treat Cancer
The combination of a cholesterol-lowering drug, Bezafibrate, and a contraceptive steroid, Medroxyprogesterone Acetate, could be an effective, non-toxic treatment …
Researchers 
7/15/13 
Scientists at NCI Generate Largest Data Set of Cancer-related Genetic Variations
PHILADELPHIA — Scientists at the National Cancer Institute (NCI) have generated a data set of cancer-specific genetic variations and …
Oncogenes 
12/17/13 
Study Finds Known Lung Cancer Oncogenes ALK And ROS1 Also Drive Colorectal Cancer
A University of Colorado Cancer Center study published online ahead of print in the journal Molecular Cancer Research shows …
Cancer 
4/21/14 
'Dustman' Protein Helps Bin Cancer Cells
Cancer researchers have discovered a new 'dustman' role for a molecule that helps a drug kill cancer cells according …
Bone 
2/12/13 
★★★ 
Emerging Cancer Drugs May Drive Bone Tumors
Cancer drugs should kill tumors, not encourage their spread. But new evidence suggests that an otherwise promising class of …
Macrophages 
11/5/14 
Bone Drug Should Be Seen in a New Light for Its Anti-cancer Properties
Australian researchers have shown why calcium-binding drugs commonly used to treat people with osteoporosis, or with late-stage cancers that …
Patients 
7/26/10 
Predicting Drug Responsiveness in Cancer Patients
Drugs such as everolimus that target the protein mTOR are used to treat several forms of cancer, but not …
Cancer 
12/7/12 
Protein Tied to Cancer-drug Resistance in Mice
SAN ANTONIO, TX (December 7, 2012)—Blocking a specific protein renders tumors more vulnerable to treatment in mice, suggesting new …
More » 
 
© Newsline Foundation  |  About  |  Privacy Policy  |  Feedback  |  Mobile